0001209191-23-059268.txt : 20231219
0001209191-23-059268.hdr.sgml : 20231219
20231219194430
ACCESSION NUMBER: 0001209191-23-059268
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20221009
FILED AS OF DATE: 20231219
DATE AS OF CHANGE: 20231219
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Lim Seah H.
CENTRAL INDEX KEY: 0001949484
ORGANIZATION NAME:
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-35527
FILM NUMBER: 231499026
MAIL ADDRESS:
STREET 1: 21250 HAWTHORNE BLVD.
STREET 2: SUITE 800
CITY: TORRANCE
STATE: CA
ZIP: 90503
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Emmaus Life Sciences, Inc.
CENTRAL INDEX KEY: 0000822370
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
ORGANIZATION NAME: 03 Life Sciences
IRS NUMBER: 870419387
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 21250 HAWTHORNE BOULEVARD, SUITE 800
CITY: TORRANCE
STATE: CA
ZIP: 90503
BUSINESS PHONE: 310-214-0065
MAIL ADDRESS:
STREET 1: 21250 HAWTHORNE BOULEVARD, SUITE 800
CITY: TORRANCE
STATE: CA
ZIP: 90503
FORMER COMPANY:
FORMER CONFORMED NAME: MYnd Analytics, Inc.
DATE OF NAME CHANGE: 20151211
FORMER COMPANY:
FORMER CONFORMED NAME: CNS RESPONSE, INC.
DATE OF NAME CHANGE: 20070313
FORMER COMPANY:
FORMER CONFORMED NAME: STRATIVATION, INC.
DATE OF NAME CHANGE: 20051115
4
1
doc4.xml
FORM 4 SUBMISSION
X0508
4
2022-10-09
0
0000822370
Emmaus Life Sciences, Inc.
EMMA
0001949484
Lim Seah H.
21250 HAWTHORNE BLVD.
SUITE 800
TORRANCE
CA
90503
1
0
0
0
0
Common stock, $0.001 par value
2022-10-09
4
P
0
25400
0.11
A
63900
D
Common stock, $0.001 par value
2023-08-25
4
P
0
92100
0.27
A
156000
D
Common stock, $0.001 par value
2023-08-30
4
P
0
20000
0.15
A
176000
D
Common stock, $0.001 par value
2023-09-05
4
P
0
1700
0.15
A
177700
D
Common stock, $0.001 par value
2023-12-15
4
S
0
6000
0.11
D
171700
D
Common stock, $0.001 par value
2023-12-15
4
J
0
4447426
0.29
A
4619126
D
Promissory Note due 9/16/2025
0.29
2023-12-15
4
J
0
240000
D
Common Stock
240000
0
D
The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $0.20 to $0.27, inclusive. The reporting person undertakes to provide to Emmaus Life Sciences, Inc., any security holder of Emmaus Life Sciences, Inc., and the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote (1).
The shares shown were issued in exchange for principal and accrued interest under the promissory note of the Issuer held by the reporting person referred to in footnote (2), below, which promissory note was surrendered by the reporting person for cancellation.
Promissory Note due 9/16/2025 surrendered for cancellation in exchange for shares of common stock referred to in footnote (1) above.
Represent shares previously issuable upon maturity of the Promissory Note due 9/16/2025.
Seah H. Lim
2023-12-19